142 related articles for article (PubMed ID: 35850183)
21. Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy.
Zhang G; Liu F; Jia E; Jia L; Zhang Y
Drug Deliv; 2016 May; 23(4):1393-7. PubMed ID: 26165422
[TBL] [Abstract][Full Text] [Related]
22. Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy.
Du M; Yin J
Drug Des Devel Ther; 2022; 16():4139-4149. PubMed ID: 36506793
[TBL] [Abstract][Full Text] [Related]
23. Curcumin-loaded nanostructured lipid carriers prepared using Peceol™ and olive oil in photodynamic therapy: development and application in breast cancer cell line.
Kamel AE; Fadel M; Louis D
Int J Nanomedicine; 2019; 14():5073-5085. PubMed ID: 31371948
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D-Loaded Nanostructured Lipid Carrier (NLC): A New Strategy for Enhancing Efficacy of Doxorubicin in Breast Cancer Treatment.
Sabzichi M; Mohammadian J; Mohammadi M; Jahanfar F; Movassagh Pour AA; Hamishehkar H; Ostad-Rahimi A
Nutr Cancer; 2017; 69(6):840-848. PubMed ID: 28742387
[TBL] [Abstract][Full Text] [Related]
25. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
Shan F; Shao Z; Jiang S; Cheng Z
Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
[TBL] [Abstract][Full Text] [Related]
26. Hyaluronic acid-coated cationic nanostructured lipid carriers for oral vincristine sulfate delivery.
Gao X; Zhang J; Xu Q; Huang Z; Wang Y; Shen Q
Drug Dev Ind Pharm; 2017 Apr; 43(4):661-667. PubMed ID: 28043185
[TBL] [Abstract][Full Text] [Related]
27. Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy.
Lin M; Teng L; Wang Y; Zhang J; Sun X
Drug Deliv; 2016 May; 23(4):1420-5. PubMed ID: 26203688
[TBL] [Abstract][Full Text] [Related]
28. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy.
Jiang H; Pei L; Liu N; Li J; Li Z; Zhang S
Drug Deliv; 2016 May; 23(4):1379-82. PubMed ID: 26162024
[TBL] [Abstract][Full Text] [Related]
29. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
30. Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition.
Ganthala PD; Alavala S; Chella N; Andugulapati SB; Bathini NB; Sistla R
Colloids Surf B Biointerfaces; 2022 Mar; 211():112305. PubMed ID: 34998178
[TBL] [Abstract][Full Text] [Related]
31. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
32. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks.
Elmowafy M; Ibrahim HM; Ahmed MA; Shalaby K; Salama A; Hefesha H
Drug Deliv; 2017 Nov; 24(1):932-941. PubMed ID: 28617150
[TBL] [Abstract][Full Text] [Related]
33. Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system.
Zhang S; Lu C; Zhang X; Li J; Jiang H
Drug Deliv; 2016 Jun; 23(5):1838-45. PubMed ID: 26879035
[TBL] [Abstract][Full Text] [Related]
34. Development, in vitro and in vivo evaluation of miltefosine loaded nanostructured lipid carriers for the treatment of Cutaneous Leishmaniasis.
Khan AS; Ud Din F; Ali Z; Bibi M; Zahid F; Zeb A; Mujeeb-Ur-Rehman ; Khan GM
Int J Pharm; 2021 Jan; 593():120109. PubMed ID: 33253802
[TBL] [Abstract][Full Text] [Related]
35. Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells.
Mohammadian J; Mahmoudi S; Pourmohammad P; Pirouzpanah M; Salehnia F; Maroufi NF; Samadi N; Sabzichi M
Naunyn Schmiedebergs Arch Pharmacol; 2020 Dec; 393(12):2315-2323. PubMed ID: 32653978
[TBL] [Abstract][Full Text] [Related]
36. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
37. Utilization of a nanostructured lipid carrier encapsulating pitavastatin-
Felimban RI; Tayeb HH; Chaudhary AG; Felemban MA; Alnadwi FH; Ali SA; Alblowi JA; ALfayez E; Bukhary D; Alissa M; Qahl SH
Drug Deliv; 2023 Dec; 30(1):83-96. PubMed ID: 36510636
[TBL] [Abstract][Full Text] [Related]
38. Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
Hong SW; Park NS; Noh MH; Shim JA; Ahn BN; Kim YS; Kim D; Lee HK; Hur DY
Lung Cancer; 2017 Apr; 106():115-124. PubMed ID: 28285685
[TBL] [Abstract][Full Text] [Related]
39. S-Protected thiolated nanostructured lipid carriers exhibiting improved mucoadhesive properties.
Arshad S; Masood-Ur-Rehman ; Hussain Asim M; Nazir I; Shahzadi I; Mousli M; Bernkop-Schnürch A
Int J Pharm; 2020 Sep; 587():119690. PubMed ID: 32738459
[TBL] [Abstract][Full Text] [Related]
40. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations.
Mahmood A; Rapalli VK; Gorantla S; Waghule T; Singhvi G
Drug Deliv Transl Res; 2022 May; 12(5):1118-1135. PubMed ID: 33895936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
